Valuing lives and providing premium and personalized healthcare services is the promise and commitment that makes Makati Medical Center (MakatiMed) the premier hospital in the Philippines for over 45 years. Located at the heart of the country’s primary central business district, MakatiMed with 600-bed capacity delivers quality and compassionate service through its highly skilled and board-certified physicians, compassionate nurses, competent allied healthcare professionals and management staff, modern facilities and state-of-the-science medical equipment and technology.
MakatiMed is committed to deliver best practices in healthcare, stringent safety standards and excellent patient care. Company are accredited by the Department of Health (DOH) and PhilHealth’s Benchbook of standards as a Center of Excellence, and is accredited as a Mother-Baby Friendly Hospital under the Mother-Baby Friendly Hospital Initiative (MBFHI) program of the DOH, the United Nations Children’s Fund (UNICEF), and the World Health Organization (WHO).
Company are also accredited by international certification body, Joint Commission International (JCI), a public acknowledgement of our world-class services and our continued dedication to superior patient care.
MakatiMed has a longstanding commitment to tirelessly upgrade the level of patient safety in the Philippines. Company's Cellular Therapeutics Center made MakatiMed one of only four hospitals that received accreditation from the DOH as a hospital-based facility engaging in cell-based therapy in the Philippines. The Makati Medical Center-Institutional Review Board (MMC-IRB) is recognized by the Forum for Ethical Review Committees in Asia and the Western Pacific, a seal of international approval for MakatiMed’s ethics review committee. The MMC-IRB is also awarded the highest level of accreditation (Level III) by the Philippine Health Research Ethics Board, giving it the privilege to be part of the Ethics Review Resource Committees of the Philippine Food and Drug Administration (FDA). As such, it can be called upon by the FDA to conduct reviews on its behalf, as well as review new drugs or device protocols where results will be submitted in support of registration for marketing authorization.